...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris.
【24h】

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris.

机译：Alefacept减少寻常型牛皮癣中的浸润性T细胞，活化的树突状细胞和炎性基因。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Psoriasis vulgaris, a skin disease that is considered to be the result of a type 1 autoimmune response, provides an opportunity for studying the changes that occur in a target-diseased tissue during innovative immunotherapies. To gain a more comprehensive picture of the response to an approved biological therapy, we studied alfacept, which is a CD2 binding fusion protein. We examined T cells, dendritic cells (DCs), and expression of a number of inflammatory genes. In 22 patients, 55% demonstrated a clear histological remission of the disease, with a 73% reduction in lesional lymphocytes and a 79% decrease in infiltrating CD8+ cells. Only histological responders showed marked reductions in the tissue expression of inflammatory genes IFN-gamma, signal transducer and activator of transcription 1, monokine induced by IFN-gamma, inducible NO synthase, IL-8, and IL-23 subunits. Parallel decreases in CD83+ and CD11c+ DCs also were measured by immunohistochemistry. Because we observed that alefacept binds primarily to T cells and not DCs, we suggest that T cells are the primary target for therapy, but that DCs and a spectrum of type 1 inflammatory genes are coordinately suppressed.
机译：寻常型牛皮癣是一种被认为是1型自身免疫反应的结果的皮肤病，它为研究创新免疫疗法期间靶标病变组织中发生的变化提供了机会。为了获得对批准的生物疗法反应的更全面的了解，我们研究了alfacept（一种CD2结合融合蛋白）。我们检查了T细胞，树突状细胞（DC）和许多炎症基因的表达。在22名患者中，有55％表现出明显的组织学缓解，病变淋巴细胞减少了73％，浸润CD8 +细胞减少了79％。仅组织学应答者显示炎性基因IFN-γ，信号转导子和转录激活因子1的组织表达显着降低，IFN-γ诱导的单因子，诱导型NO合酶，IL-8和IL-23亚基。还通过免疫组织化学测量了CD83 +和CD11c + DC的平行减少。因为我们观察到alefacept主要与T细胞结合而不与DC结合，所以我们建议T细胞是治疗的主要靶标，但是DC和1型炎症基因的光谱被协同抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号